Abstract
Summary
Tumor genomics, also known as cancer genomics, is an emerging sub-discipline in genomics, mainly through the high-throughput sequencing technology to associate genes with cancer. Tumor is a disease caused by the accumulation of DNA mutations that leads to an uncontrolled proliferation of cells and the formation of new organisms. The main goal of tumor genomics is to provide new methods for tumor diagnosis, tumor clinical outcome prediction and tumor target treatment by identifying new oncogenes or tumor suppressor genes.
The global market for Tumor Genomics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Tumor Genomics include Abbott Laboratories, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, General Electric Company, Illumina, Inc. and Merck KGaA, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Genomics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Tumor Genomics by region & country, by Type, and by Application.
The Tumor Genomics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Genomics.
Market Segmentation
By Company
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Segment by Type:
Assays and Kits
Instrument
Segment by Application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Tumor Genomics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Tumor Genomics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Tumor Genomics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Tumor Genomics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Tumor Genomics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Tumor Genomics include Abbott Laboratories, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, General Electric Company, Illumina, Inc. and Merck KGaA, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Genomics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Tumor Genomics by region & country, by Type, and by Application.
The Tumor Genomics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Genomics.
Market Segmentation
By Company
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Segment by Type:
Assays and Kits
Instrument
Segment by Application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Tumor Genomics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Tumor Genomics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Tumor Genomics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Tumor Genomics Product Introduction
1.2 Global Tumor Genomics Market Size Forecast
1.3 Tumor Genomics Market Trends & Drivers
1.3.1 Tumor Genomics Industry Trends
1.3.2 Tumor Genomics Market Drivers & Opportunity
1.3.3 Tumor Genomics Market Challenges
1.3.4 Tumor Genomics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tumor Genomics Players Revenue Ranking (2023)
2.2 Global Tumor Genomics Revenue by Company (2019-2024)
2.3 Key Companies Tumor Genomics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Tumor Genomics Product Offered
2.5 Key Companies Time to Begin Mass Production of Tumor Genomics
2.6 Tumor Genomics Market Competitive Analysis
2.6.1 Tumor Genomics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Tumor Genomics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Genomics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Assays and Kits
3.1.2 Instrument
3.2 Global Tumor Genomics Sales Value by Type
3.2.1 Global Tumor Genomics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Tumor Genomics Sales Value, by Type (2019-2030)
3.2.3 Global Tumor Genomics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Diagnostics and Monitoring
4.1.2 Drug Discovery and Development
4.1.3 Biomarker Discovery
4.2 Global Tumor Genomics Sales Value by Application
4.2.1 Global Tumor Genomics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Tumor Genomics Sales Value, by Application (2019-2030)
4.2.3 Global Tumor Genomics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Tumor Genomics Sales Value by Region
5.1.1 Global Tumor Genomics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Tumor Genomics Sales Value by Region (2019-2024)
5.1.3 Global Tumor Genomics Sales Value by Region (2025-2030)
5.1.4 Global Tumor Genomics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Tumor Genomics Sales Value, 2019-2030
5.2.2 North America Tumor Genomics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Tumor Genomics Sales Value, 2019-2030
5.3.2 Europe Tumor Genomics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Tumor Genomics Sales Value, 2019-2030
5.4.2 Asia Pacific Tumor Genomics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Tumor Genomics Sales Value, 2019-2030
5.5.2 South America Tumor Genomics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Tumor Genomics Sales Value, 2019-2030
5.6.2 Middle East & Africa Tumor Genomics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tumor Genomics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Tumor Genomics Sales Value
6.3 United States
6.3.1 United States Tumor Genomics Sales Value, 2019-2030
6.3.2 United States Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Tumor Genomics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Tumor Genomics Sales Value, 2019-2030
6.4.2 Europe Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Tumor Genomics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Tumor Genomics Sales Value, 2019-2030
6.5.2 China Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Tumor Genomics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Tumor Genomics Sales Value, 2019-2030
6.6.2 Japan Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Tumor Genomics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Tumor Genomics Sales Value, 2019-2030
6.7.2 South Korea Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Tumor Genomics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Tumor Genomics Sales Value, 2019-2030
6.8.2 Southeast Asia Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Tumor Genomics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Tumor Genomics Sales Value, 2019-2030
6.9.2 India Tumor Genomics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Tumor Genomics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Profile
7.1.2 Abbott Laboratories Main Business
7.1.3 Abbott Laboratories Tumor Genomics Products, Services and Solutions
7.1.4 Abbott Laboratories Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.1.5 Abbott Laboratories Recent Developments
7.2 Agilent Technologies, Inc
7.2.1 Agilent Technologies, Inc Profile
7.2.2 Agilent Technologies, Inc Main Business
7.2.3 Agilent Technologies, Inc Tumor Genomics Products, Services and Solutions
7.2.4 Agilent Technologies, Inc Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.2.5 Agilent Technologies, Inc Recent Developments
7.3 Bio-Rad Laboratories, Inc.
7.3.1 Bio-Rad Laboratories, Inc. Profile
7.3.2 Bio-Rad Laboratories, Inc. Main Business
7.3.3 Bio-Rad Laboratories, Inc. Tumor Genomics Products, Services and Solutions
7.3.4 Bio-Rad Laboratories, Inc. Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.3.5 Danaher Corporation Recent Developments
7.4 Danaher Corporation
7.4.1 Danaher Corporation Profile
7.4.2 Danaher Corporation Main Business
7.4.3 Danaher Corporation Tumor Genomics Products, Services and Solutions
7.4.4 Danaher Corporation Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.4.5 Danaher Corporation Recent Developments
7.5 F. Hoffmann-La Roche Ltd
7.5.1 F. Hoffmann-La Roche Ltd Profile
7.5.2 F. Hoffmann-La Roche Ltd Main Business
7.5.3 F. Hoffmann-La Roche Ltd Tumor Genomics Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Ltd Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.5.5 F. Hoffmann-La Roche Ltd Recent Developments
7.6 Fluidigm Corporation
7.6.1 Fluidigm Corporation Profile
7.6.2 Fluidigm Corporation Main Business
7.6.3 Fluidigm Corporation Tumor Genomics Products, Services and Solutions
7.6.4 Fluidigm Corporation Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.6.5 Fluidigm Corporation Recent Developments
7.7 General Electric Company
7.7.1 General Electric Company Profile
7.7.2 General Electric Company Main Business
7.7.3 General Electric Company Tumor Genomics Products, Services and Solutions
7.7.4 General Electric Company Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.7.5 General Electric Company Recent Developments
7.8 Illumina, Inc.
7.8.1 Illumina, Inc. Profile
7.8.2 Illumina, Inc. Main Business
7.8.3 Illumina, Inc. Tumor Genomics Products, Services and Solutions
7.8.4 Illumina, Inc. Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.8.5 Illumina, Inc. Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Tumor Genomics Products, Services and Solutions
7.9.4 Merck KGaA Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.9.5 Merck KGaA Recent Developments
7.10 Myriad Genetics, Inc.
7.10.1 Myriad Genetics, Inc. Profile
7.10.2 Myriad Genetics, Inc. Main Business
7.10.3 Myriad Genetics, Inc. Tumor Genomics Products, Services and Solutions
7.10.4 Myriad Genetics, Inc. Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.10.5 Myriad Genetics, Inc. Recent Developments
7.11 Pacific Biosciences of California, Inc.
7.11.1 Pacific Biosciences of California, Inc. Profile
7.11.2 Pacific Biosciences of California, Inc. Main Business
7.11.3 Pacific Biosciences of California, Inc. Tumor Genomics Products, Services and Solutions
7.11.4 Pacific Biosciences of California, Inc. Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.11.5 Pacific Biosciences of California, Inc. Recent Developments
7.12 PerkinElmer
7.12.1 PerkinElmer Profile
7.12.2 PerkinElmer Main Business
7.12.3 PerkinElmer Tumor Genomics Products, Services and Solutions
7.12.4 PerkinElmer Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.12.5 PerkinElmer Recent Developments
7.13 QIAGEN
7.13.1 QIAGEN Profile
7.13.2 QIAGEN Main Business
7.13.3 QIAGEN Tumor Genomics Products, Services and Solutions
7.13.4 QIAGEN Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.13.5 QIAGEN Recent Developments
7.14 Siemens Healthineers AG
7.14.1 Siemens Healthineers AG Profile
7.14.2 Siemens Healthineers AG Main Business
7.14.3 Siemens Healthineers AG Tumor Genomics Products, Services and Solutions
7.14.4 Siemens Healthineers AG Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.14.5 Siemens Healthineers AG Recent Developments
7.15 Thermo Fisher Scientific Inc.
7.15.1 Thermo Fisher Scientific Inc. Profile
7.15.2 Thermo Fisher Scientific Inc. Main Business
7.15.3 Thermo Fisher Scientific Inc. Tumor Genomics Products, Services and Solutions
7.15.4 Thermo Fisher Scientific Inc. Tumor Genomics Revenue (US$ Million) & (2019-2024)
7.15.5 Thermo Fisher Scientific Inc. Recent Developments
8 Industry Chain Analysis
8.1 Tumor Genomics Industrial Chain
8.2 Tumor Genomics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tumor Genomics Sales Model
8.5.2 Sales Channel
8.5.3 Tumor Genomics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer